Two Sigma Investments’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.8M Buy
442,107
+237,951
+117% +$11.2M 0.01% 1290
2026
Q2
$11M Buy
204,156
+22,741
+13% +$1.01M 0.01% 1464
2026
Q1
$8.74M Buy
181,415
+85,872
+90% +$5.88M 0.01% 1492
2025
Q4
$6.65M Sell
95,543
-87,368
-48% -$3.57M 0.01% 1448
2025
Q3
$5.12M Buy
+182,911
New +$3.64M 0.01% 1443

Other funds holding GPCR

Two Sigma Investments's GPCR Position: Q3 2026 in Review

Two Sigma Investments increased its Structure Therapeutics (GPCR) stake by 117% in Q3 2026, buying an estimated $11.2M and bringing the position to 442,107 shares worth $13.8M. The position accounts for 0.01% of the portfolio, ranked #1290.

Two Sigma Investments first reported a position in GPCR in Q3 2025 and has held it in 5 quarters since. 172 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Two Sigma Investments held 442,107 shares of Structure Therapeutics worth $13.8M as of Q3 2026.
  • Two Sigma Investments bought 237,951 Structure Therapeutics shares in Q3 2026, an estimated $11.2M.
  • Structure Therapeutics made up 0.01% of Two Sigma Investments's portfolio in Q3 2026, its #1290 holding.
  • Two Sigma Investments first reported a position in Structure Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.